A-Alpha Bio wins $620,472 NSF Phase II SBIR to develop molecular-glue discovery system

Seattle startup A-Alpha Bio received a $620,472 NSF Phase II SBIR grant to develop a system that identifies molecular glues which tag disease-causing proteins for cellular degradation, aiming to target previously 'undruggable' proteins for diseases like Alzheimer’s, cancer and autoimmune disorders.

RRandolph Lopez DDavid Younger AA-Alpha Bio UUniversity of Washington GGates Foundation